Bonum Therapeutics
Business Services · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1150 Eastlake Ave E Ste 1100, Seattle, W...Phone Number
(206) 888-8485Website
www.bonumtx.comRevenue
$7 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Bonum Therapeutics
Bonum Therapeutics is a biotechnology company developing antibody-controlled protein therapeutics that activate only at disease sites. Its dual-binding platform is designed to deliver targeted cytokine medicines for cancer while extending into autoimmune disease, metabolic disorders, and pain management through preclinical pipeline development work.Explore more
Bonum Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bonum Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Bonum Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Bonum Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Bonum Therapeutics recently announced quarterly report
Click to see if Bonum Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Bonum Therapeutics
Check out if Bonum Therapeutics is spiking on competitors!
Product Launch: Get notified when Bonum Therapeutics launches new products
Funding: Get notified immidiatlly once Bonum Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Bonum Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Bonum Therapeutics
Compare insights from companies similar to Bonum Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Bonum Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Bonum Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Bonum Therapeutics.
Bonum Therapeutics financials insights
Gather financial insights about Bonum Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$93M
2026
Stock/Share Issuance
$26.9M
Bonum Therapeutics Tech Stack
A closer look at the technologies used by Bonum Therapeutics
Most Recent Scoops
Funding
Funding
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Executive Move
Executive Moves, Board of Directors
Facilities Relocation / Expansion
Hiring Plans
Hiring Plans, Facilities Relocation/Expansion
Promotion
Executive Move
Bonum Therapeutics News & Media
Bonum Therapeutics Appoints Samuel C. Blackman, MD, PhD, to its Board of Directors
SEATTLE--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using innovative technology for conditional activation of biologics to create highly active and less toxic medicines, today announced that Samuel C. Blackman, MD, PhD, has joined its board of directors as an independent director. Blackman, a pediatric neuro-oncologist by training, is the co-founder and head of research and development at Day One Biopharmaceuticals, which is dedicated to developing and commercializingSeattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs
Bonum Therapeutics is moving into new offices near Seattle’s South Lake Union neighborhood and plans to double its headcount in pursuit of immunotherapy drugs. The biotech startup will occupy the 11th floor of the Alexandria’s new life science tower at 1150 Eastlake Ave. E. “We’re very excited about 1150,” said CEO John Mulligan. “It’s beautiful, great views. It’ll be a really fun space.” Mulligan said Bonum discovered the vacancy during the biotech downturn in 2022. The AlexandriaBonum Therapeutics to Present on its Novel Platform for Generating Conditionally Activated Targeted Therapies at Keystone Conference
SEATTLE--(BUSINESS WIRE)--Bonum Therapeutics, a biotechnology company that is using its proprietary platform for conditional regulation to create highly active and less toxic medicines, today announced that it will present data on a new class of protein therapeutics with the potential for increased safety and efficacy in a wide range of biologic targets and disease areas. Scientists from Bonum will present two posters at the upcoming Keystone Symposium, “Antibodies as Drugs: The Art in AntibodyBonum Therapeutics to Present Poster on Lead Program at AACR 2024
SEATTLE--(BUSINESS WIRE)-- #AACR--Bonum Therapeutics, a biopharmaceutical company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, today announced the first public presentation of preclinical data on its lead program, a conditionally active LAG3-IL2 therapeutic. Scientists from Bonum will present these data in a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Bonum Therapeutics
Sign Up For FreeTo access detailed company insights
Bonum Therapeutics is a biotechnology company developing antibody-controlled protein therapeutics that activate only at disease sites. Its dual-binding platform is designed to deliver targeted cytokine medicines for cancer while extending into autoimmune disease, metabolic disorders, and pain management through preclinical pipeline development work... Read More
